|
|
|
Welcome to the Quality Counts. For those health conscious consumers and medical professionals that are looking to purchase nutritional supplements, vitamins, herbs, learning about medications, losing weight, health food, low carbs, high protein nutrition, and exercise, you have come to the right place. Quality Counts serves both the medical practitioner and consumer interested in nutritional therapy and alternative medicine.
Home > Anti-aging Research > Statins > Crestor
(rosuvastatin)
Crestor (rosuvastatin)
Where to purchase:
Related Topics:
Alternative News:
News & Research:
-
No Efficacy Benefits Seen With Rosuvastatin Against Placebo in GISSI-HF
Trial of Symptomatic Chronic Heart Failure - Doctor's Guide, 9/2/08 -
"At a median follow-up of 3.9 years, the researchers
found no difference in results for time to all-cause mortality, Dr. Tognoni
said, with 28.1% for placebo and 28.8% for rosuvastatin and an adjusted
hazard ratio (aHR) of 1.00 (P = .943). All-cause mortality or
hospitalisation for cardiovascular reasons also showed no difference, at
56.1% and 57.1%, respectively"
-
Statin Drug Crestor Slows Artery Plaque - WebMD, 4/1/08 -
"A trial of the statin drug Crestor [rosuvastatin]
has been halted early due to "unequivocal evidence" that it reduces heart
attacks, strokes, and deaths due to cardiovascular disease in people with no
signs of heart disease" - See rosuvastatin at OffshoreRX.com
 .
-
Crestor May Not Cut Heart Failure Death - WebMD, 11/28/07
-
New Crestor(R) (rosuvastatin calcium) Indication Approved in U.S. to Slow
Progression of Atherosclerosis in Patients With High Cholesterol -
Doctor's Guide, 11/15/07 - "The U.S. Food and Drug
Administration (FDA) has approved Crestor(R) (rosuvastatin calcium) as an
adjunct to diet to slow the progression of atherosclerosis in patients with
elevated cholesterol"
-
Carotid Artery Thickening Slowed With Rosuvastatin Therapy - Doctor's
Guide, 11/8/07 - "228 patients on rosuvastatin with
less than two risk factors for heart disease and thinner carotid intima
showed a progression of thickness growth at the rate of.0007 mm/year, while
the average growth in thickness among the 76 placebo patients was.0123
mm/year, a difference that was statistically significant"
-
CORONA: Little Clinical Benefit Seen in First Major Statin Trial in HF -
Medscape, 11/6/07 - "Over a median follow-up of 33
months, there were no significant differences in the primary end point or in
all-cause mortality, the rate of coronary events (which included sudden
death, fatal or nonfatal MI, percutaneous coronary intervention [PCI] or
coronary arterial bypass graft [CABG], resuscitated cardiac arrest, and
hospitalization for unstable angina), effects on NYHA class, or the rate of
newly diagnosed diabetes ... Despite the lack of difference in the primary
end point, there were significant reductions in levels of CRP; however, they
were not decreased to what would be considered a low level ... This does
bring into question whether higher doses of rosuvastatin could have
additional clinical benefit" - Note: Statins do little to
increase HDL which some studies imply may be more important. Also,
statins have been shown to decrease co-enzyme Q10. I would have liked
to see the results if they had added niacin to increase HDL and co-enzyme
Q10.
-
Crestor Halts Artery Thickening - WebMD, 3/26/07 -
"in people on Crestor, the thickness
of the artery wall dropped by 0.0014 millimeters a year. In contrast, it
thickened by about 0.013 millimeters per year in those on placebo"
-
New EXPLORER Results Show Patients Achieved Dramatic Reductions in
C-Reactive Protein And LDL-C Levels With Rosuvastatin Combination Therapy
- Doctor's Guide, 9/6/06
-
Biggest LDL-C Reduction Ever Shown in Patients Is Achieved With
Rosuvastatin/Ezetimibe Combination - Doctor's Guide, 6/20/06
-
New Study Showed Ezetimibe/Simvastatin Significantly More Effective Than
Rosuvastatin at Lowering LDL Cholesterol at all Doses Compared -
Doctor's Guide, 6/19/06
-
Rosuvastatin: An Independent Analysis of Risks and Benefits - Medscape,
6/14/06
-
Rosuvastatin Helped More Patients Reach Goal in MERCURY II Study -
Doctor's Guide, 5/15/06
-
Intensive Statin Therapy Useful in High-Risk Coronary Patients - Doctor's
Guide, 3/13/06 - "very high-intensity
statin therapy using rosuvastatin 40 mg/day induces regression of coronary
atherosclerosis ... treatment decreased LDL-C to 60.8 mg/dL while increasing
HDL-C by 14.7%"
-
Statins May Reverse Plaque Buildup
- WebMD, 3/13/06
-
New Data Examines Effects of Crestor Alone or in Combination with Another
Therapy in High Risk Patients with Very High Cholesterol - Doctor's
Guide, 11/22/05
-
Rosuvastatin Appears Safe and Effective for Treating Hyperlipidemia in
Diabetic Patients with Chronic Kidney Disease - Doctor's Guide, 11/11/05
-
Direct Comparison Shows Rosuvastatin Achieves Greater Reductions than
Atorvastatin in LDL-C - Doctor's Guide, 10/27/05
-
Crestor (Rosuvastatin) May Be Associated With Arrested Progression of
Atherosclerosis and Regression of Plaques at Sites With The Most Disease
- Doctor's Guide, 5/6/05
- FDA warns of risks from AstraZeneca’s Crestor - MSNBC, 3/2/05
- Crestor (Rosuvastatin) Appears To Helps More African-American Patients Achieve Cholesterol Goals - Doctor's Guide, 11/16/04
- Rosuvastatin Provides Better Rates of Lipid Lowering Compared to Other Statins - Doctor's Guide, 10/27/04 -
"switching to rosuvastatin from
another statin agent helped more patients achieve primary treatment goals for low-density lipoprotein cholesterol (LDL-C) and secondary apolipoprotein
(apo)
B treatment goals in coronary heart disease (CHD) patients with high lipid levels"
- Rosuvastatin Shows Better Results in Lipid Parameters Among Diabetic Patients - Doctor's Guide, 10/25/04
- Rosuvastatin May Be Better Than Atorvastatin in Patients With Metabolic Syndrome - Doctor's Guide, 10/25/04 -
"The benefits of rosuvastatin were
seen in levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apoprotein (apo) A-I
and apo B, total cholesterol and non-HDL-C"
- Cholesterol Drug Safety Questioned - WebMD, 5/18/04 -
"a citizen group has renewed its call for the FDA to ban the cholesterol-lowering drug Crestor ...
there have been 11 new cases of the muscle-destroying condition -- rhabdomyolysis -- and three additional cases of kidney damage in people taking Crestor"
- Statins Effectively Lower Cholesterol, But Experts Debate First Choice - Medscape, 3/15/04 -
"HDL cholesterol levels were increased more than 10% with
rosuvastatin 40 mg, nearly 5% with atorvastatin 80 mg, 10% with 40 mg simvastatin, and 6.4% with 40 mg pravastatin"
- Rosuvastatin Lowers Cholesterol Most in Metabolic Syndrome Patients - Doctor's Guide, 3/10/04 -
"In a comparison of 4 cholesterol-lowering
drugs, rosuvastatin (Crestor) resulted in the greatest reductions in low-density lipoprotein (LDL) cholesterol ... rosuvastatin also was better than the other statins in raising high density lipoprotein [HDL] cholesterol and in lowering triglycerides"
- Group Asks FDA to Ban Cholesterol Drug - WebMD, 3/5/04
- Group seeks ban of latest statin because of muscle side effect - USA Today, 3/4/04 -
"A 39-year-old woman has died of a
muscle-destroying condition linked to the controversial new anti-cholesterol drug Crestor ... Crestor also was linked to some cases of kidney abnormalities not seen with other statins"
- Lancet Takes Aim at Rosuvastatin in Blistering Editorial - Medscape, 10/23/03 -
"More than 80% of patients reach their [low-density lipoprotein cholesterol] goals on the starting
dose of 10 mg, which also significantly increases [high-density lipoprotein cholesterol], a profile unmatched by competitor drugs ... Dr Horton added that there is no evidence to support prescribing rosuvastatin over "simvastatin or
atorvastatin ... The FDA approved the drug in August at 5-, 10-, and 20-mg doses. An 80-mg dose application was withdrawn by AstraZeneca because of safety concerns about increased risk of
rhabdomyolysis, which was the same adverse effect that triggered the withdrawal of Bayer's cerivastatin (Baycol) in 2001. In the Lancet editorial, Dr. Horton wrote that some critics raise similar criticisms about rosuvastatin at the 40-mg dose, which the FDA
approved under restricted distribution. He noted in the interview with Medscape that Public Citizen, a U.S. consumer watchdog group affiliated with Ralph Nader, has issued a "Do Not Use" warning about rosuvastatin"
- Study Confirms Benefit Of New Statin, Crestor (Rosuvastatin), In 'Real Life Setting - Doctor's Guide, 10/8/03 -
"substantially more patients
(more than three quarters) achieved the recommended NSF for CHD cholesterol targets1 when treated with rosuvastatin compared to other statins"
- Rosuvastatin Improves Plasma Lipid Ratios - Doctor's Guide, 10/1/03 -
"Rosuvastatin significantly more
effective than atorvastatin, simvastatin, and pravastatin in improving the ratios of total cholesterol to high-density lipoprotein cholesterol" - See
Crestor (rosuvastatin)
 at drugstore.com.
- Rosuvastatin 10-40 mg Safe and Well Tolerated Compared to Other Statins - Doctor's Guide, 10/1/03 -
"Minor adverse events associated with the
use of rosuvastatin included myalgia in 2.1%, asthenia in 1.2%, nausea in 1.4%, dyspepsia in 0.6%, headache in 1.1%, insomnia in 0.8%, abdominal pain in 1.2%, diarrhoea in 1.1%, constipation in 1.1%,
and flatulence in 0.9%"
- Rosuvastatin Improves Apolipoprotein Levels - Doctor's Guide, 10/1/03
- Crestor (Rosuvastatin Calcium) Available in US For Treatment of Elevated Cholesterol - Doctor's Guide, 9/16/03 -
"Crestor is available in 5 to
40 mg doses in pharmacies nationwide ... In clinical trials, Crestor lowered LDL (low-density lipoprotein) cholesterol or "bad" cholesterol by 45 to 63 percent (7 percent for placebo) and increased HDL (high-density lipoprotein) cholesterol or "good" cholesterol by 8 to 14 percent (3 percent for placebo)"
- Heart Protection Study Implications for Lipid Management Guidelines and Practices - Doctor's Guide, 9/16/03 -
"While Heart Protection Study (HPS) findings support
aggressive lowering of low-density lipoprotein (LDL) cholesterol levels and suggest optimal levels well below current recommendations, failure to achieve current goals for LDL cholesterol is common ... HPS findings demonstrated that a reduction of major vascular events extended even to CAD patients with initial LDL
cholesterol levels <100 mg/dL using simvastatin 40 mg, suggesting that the optimal LDL cholesterol level is below target levels established in current guidelines ... rosuvastatin is more effective than other statins in reducing LDL cholesterol"
- Cholesterol-Lowering Statin, Crestor (Rosuvastatin Calcium), Receives FDA Approval - Doctor's Guide, 8/13/03
- FDA Advisory Committee Unanimously Recommends Approval of Lipid Lowering Drug, Crestor (Rosuvastatin Calcium) - Doctor's Guide, 7/10/03
- Rosuvastatin Improves Metabolic Syndrome Risk Factors - Doctor's Guide, 4/9/03
- Rosuvastatin Achieves LDL-C Goal When Other Statins Fall Short - Doctor's Guide, 4/1/03
- Rosuvastatin More Effective Than Atorvastatin In Hypercholesterolemic Patients - Doctor's Guide, 2/13/02
- Crestor (Rosuvastatin) Superior Impact On Lipid Levels Confirmed - Doctor's Guide, 9/3/01
- New Drug [rosuvastatin] Takes a Sledgehammer to High Cholesterol - WebMD, 3/20/01
Abstracts:
Related Searches:
70702
|
